Education
About Us
Working with TipRanks
Follow Us
Opko Health Inc (OPK)
NASDAQ:OPK
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 6.75%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in the ModeX pipeline, successful global commercialization efforts for NGENLA, and substantial additional funding from BARDA for antiviral programs. However, these positive developments were tempered by a decline in Diagnostics segment revenue and operating losses, as well as increased R&D expenses and foreign currency challenges. Overall, the highlights slightly outweigh the lowlights.Company Guidance
During the OPKO Health Fourth Quarter 2024 Financial Results Conference Call, guidance for the upcoming year emphasized several key metrics. The company anticipates total revenues for 2025 to range between $675 million and $700 million, which includes service revenue of $405 million to $425 million, product revenue of $165 million to $175 million, and other revenue of $80 million to $95 million. This other revenue is expected to include a Pfizer gross profit share of $35 million to $45 million and BARDA revenue of $40 million to $48 million. Costs and expenses are projected to be between $825 million and $875 million, with research and development expenses estimated at $120 million to $140 million. The company plans to end 2025 with at least $300 million in cash and cash equivalents, after considering capital expenditures and potential non-dilutive financing transactions or third-party collaborations.ModeX Pipeline Progress
Two programs entered Phase 1 clinical trials, with advancements in multispecific antibody technology and nanoparticle vaccine platform.
NGENLA Commercialization
Pfizer is expanding global sales of NGENLA in 42 countries, converting patients from daily to weekly administration.
EBV Vaccine Collaboration with Merck
Achieved a milestone payment for entering the clinic, eligible for up to $860 million in future milestone payments and royalties.
BARDA Funding for Antiviral Programs
$51 million additional funding awarded for COVID multispecific antibody and broadly neutralizing influenza antibodies, with potential total funding of $205 million.
Financial Realignment and Capital Structure
Significant cash infusion allowing for capital returns to shareholders and advancement of the pharmaceutical pipeline.
Diagnostics Segment Restructuring
BioReference Health restructuring led to reduced costs and improved operating results, downsizing workforce from 3,300 to 2,000.
Overall Revenue Growth in Pharmaceutical Segment
Revenue increased to $80.5 million in Q4 2024 from $57.7 million in 2023, driven by milestones and product sales.
---
OPK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OPK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $1.63 | $1.74 | +6.75% |
| Nov 07, 2024 | $1.45 | $1.52 | +4.83% |
| Aug 07, 2024 | $1.28 | $1.43 | +11.72% |
| May 07, 2024 | $1.30 | $1.25 | -3.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Opko Health Inc (OPK) report earnings?
Opko Health Inc (OPK) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Opko Health Inc (OPK) earnings time?
Opko Health Inc (OPK) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OPK EPS forecast?
OPK EPS forecast for the fiscal quarter 2024 (Q4) is -0.09.
---